Nat T, Dr. Rubinfeld is one of the four origina
Post# of 135
Posted On: 09/22/2014 11:23:31 PM
Re: Natural Treasures #11
Nat T,
Dr. Rubinfeld is one of the four original co-founders of Amgen.
Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb.
Dr. Rubinfeld is credited with inventing Amoxicillin , biodegradable detergent and the 10 second Polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
He said this nearly two years ago...
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
And just 2 weeks ago Amarantus Announces Positive MANF Ocular Toxicology Data
today announced positive 15-day non-GLP toxicology data for a single intravitreal administration of MANF in an ocular safety animal model, relevant to MANF's development in ocular diseases, including orphan indications
http://ir.amarantus.com/company-news/detail/1...ology-data
Dr. Rubinfeld clearly knows what he speaks of. I am curious, since you've had the history you have with Amgen, and I only know it by its name and Stock status, what comparisons might you make seeing where AMBS is now to where Amgen was?
Very much appreciated.
Dr. Rubinfeld is one of the four original co-founders of Amgen.
Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb.
Dr. Rubinfeld is credited with inventing Amoxicillin , biodegradable detergent and the 10 second Polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
He said this nearly two years ago...
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
And just 2 weeks ago Amarantus Announces Positive MANF Ocular Toxicology Data
today announced positive 15-day non-GLP toxicology data for a single intravitreal administration of MANF in an ocular safety animal model, relevant to MANF's development in ocular diseases, including orphan indications
http://ir.amarantus.com/company-news/detail/1...ology-data
Dr. Rubinfeld clearly knows what he speaks of. I am curious, since you've had the history you have with Amgen, and I only know it by its name and Stock status, what comparisons might you make seeing where AMBS is now to where Amgen was?
Very much appreciated.
(0)
(0)